[1] Anwar SD, Foster C, Ashraf A. Lipid disorders and metabolic-associated fatty liver disease. Endocrinol Metab Clin North Am, 2023, 52(3):445-457. [2] Badmus OO, Hinds TD Jr, Stec DE. Mechanisms linking metabolic-associated fatty liver disease (mafld) to cardiovascular disease. Curr Hypertens Rep, 2023,25(8):151-162. [3] Zeng XF, Varady KA, Wang XD, et al. The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: an international multidisciplinary expert consensus. Metabolism, 2024, 161:156028. [4] 陈慧慧,王乾皓,陈润花,等.中药代茶饮干预非酒精性脂肪性肝病湿热蕴结证的临床研究.中华中医药杂志,2023,38(2):902-905. [5] Fu L, Huang L, Gao Y, et al. Investigating the efficacy of acupuncture in treating patients with metabolic-associated fatty liver disease: a protocol for a randomised controlled clinical trial. BMJ Open, 2024, 14(9):e081293. [6] 中华医学会肝病学分会,范建高,南月敏,等. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版). 实用肝脏病杂志,2024,27(4):494-510. [7] 中华中医药学会脾胃病分会.非酒精性脂肪性肝病中医诊疗专家共识(2023年).中国中西医结合消化杂志,2024,32(1):1-7. [8] Zhou Y, Shen Y, He J, et al. Clinical effectiveness of entecavir versus tenofovir disoproxil fumarate tablets in chronic hepatitis B treatment. Am J Transl Res, 2024, 16(12):7591-7599. [9] Zhao J, Zhao X, Wang Q, et al. Efficacy and safety of electroacupuncture for metabolic dysfunction-associated fatty liver disease: A study protocol for a multicentre, randomised, sham acupuncture-controlled, patient-blinded clinical trial. BMJ Open, 2024, 14(11):e084768. [10] 谢爱萍,赵景,蒋祁明,等. 超声声衰减系数与受控衰减参数联合肝脏硬度检测诊断NAFLD患者NASH发生效能研究. 实用肝脏病杂志,2024,27(5):705-708. [11] Kim J, Jung KH, Choi JG, et al. Artemisiae iwayomogii herba inhibits growth, motility, and the pi3k/akt/mtor signaling pathway in hepatocellular carcinoma cells. Planta Med, 2020, 86(10):717-727. [12] Liu J, Shi Y, Peng D,et al. Salvia miltiorrhiza bge (danshen) in the treating non-alcoholic fatty liver disease based on the regulator of metabolic targets. Front Cardiovasc Med, 2022, 22(9):842980. [13] Tang BX, Zhang Y, Sun DD, et al. Luteolin-7-diglucuronide, a novel ptp1b inhibitor, ameliorates hepatic stellate cell activation and liver fibrosis in mice. Acta Pharmacol Sin, 2025, 46(1):122-133. [14] Hong KD, Wan T, Lu SY. Clinical experience of acupuncture treatment for non-alcoholic fatty liver disease. Evid Based Complement Alternat Med, 2022:2447529. [15] 罗良德,苏建明,任成果,等. 复方甘草酸苷联合非诺贝特治疗代谢相关性脂肪性肝病患者疗效及其对脂代谢的影响. 实用肝脏病杂志,2023,26(5):650-653. [16] 刘云霄,郭峰,牛丽娜,等. 从非酒精性脂肪性肝病到代谢功能障碍相关脂肪性肝病-基于临床特征差异分析. 中华肝脏病杂志,2024,32(4):346-353. [17] Mao K, Liu H, Cao X,et al. Hawthorn or semen cassiae-alleviated high-fat diet-induced hepatic steatosis in rats via the reduction of endoplasmic reticulum stress. Food Funct, 2022, 13(23):12170-12181. [18] Ding M, Zhou F, Li Y, et al. Cassiae semen improves non-alcoholic fatty liver disease through autophagy-related pathway. Chin Herb Med, 2023, 15(3):421-429. [19] Huang L, Zhu H, Tang Y, et al. Exploring the mechanism of cassiae semen in regulating lipid metabolism through network pharmacology and experimental validation. Biosci Rep, 2023, 43(2):BSR20221375. [20] Liu C, Ao Y, Liu B,et al. The safety and efficacy of acupuncture in treating nonalcoholic fatty liver disease: A systematic review and meta-analysis based on randomized controlled trials. Medicine (Baltimore), 2025, 104(18):e42272. [21] 耿烨,李艳艳.高频超声与脂肪肝指数联合评估在健康体检中诊断脂肪肝的价值.影像科学与光化学,2025,43(1):41-47. |